J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Clovis Oncology (CLVS) yesterday. The company’s shares closed last Tuesday at $5.51.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.5% and a 57.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Clovis Oncology is a Hold with an average price target of $7.67, representing a 37.0% upside. In a report released yesterday, Piper Sandler also maintained a Hold rating on the stock with a $5.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.63 and a one-year low of $3.62. Currently, Clovis Oncology has an average volume of 4.89M.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLVS in relation to earlier this year. Most recently, in November 2020, Brian Atwood, a Director at CLVS bought 6,896 shares for a total of $21,240.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.